Status:
RECRUITING
Gallium (68Ga) Edotreotide PET/CT for Imaging Patients With Gastrointestinal Pancreatic Neuroendocrine Tumors
Lead Sponsor:
Jiangsu HengRui Medicine Co., Ltd.
Conditions:
Advanced Gastroenteropancreatic Neuroendocrine Tumor
Eligibility:
All Genders
18-75 years
Phase:
PHASE3
Brief Summary
This is a single-arm imaging study using DOTATOC peptide, labelled with the Gallium (68Ga) tracer.
Eligibility Criteria
Inclusion
- Able and willing to provide a written informed consent;
- 18\~75 years old,male or female；
- ECOG performance status 0 or 1;
- Confirmed or suspicion of GEP-NET.
Exclusion
- Unable to lie flat for the entire imaging duration (e.g. persistent cough, claustrophobia, severe arthritis, etc.), unable to enter the PET/CT device;
- Individuals planning to be pregnant, and lactating women;
- Individuals with concurrent active infections or with unexplained fever \>38.5°C for more than 1 hour during the screening period or prior to administration of investigational medication.
Key Trial Info
Start Date :
February 22 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
November 1 2025
Estimated Enrollment :
66 Patients enrolled
Trial Details
Trial ID
NCT06091748
Start Date
February 22 2024
End Date
November 1 2025
Last Update
June 3 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Beijing Cancer Hospital
Beijing, Beijing Municipality, China, 100142